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A dherence to oral hypoglycemic agents used in the management of diabetes is suboptimal, yet adherence is not routinely measured in clinical practice, in part because no gold standard measurement exists. 1,2 Persistence, a measure of refill adherence, holds promise as a practical measure in systems of care where longterm pharmacy claims data are available, such as in the Veterans Administration (VA). In the VA system, calculating a persistence measurement imposes minimal burden to the provider or patient because the refill data are integrated with the electronic medical record (EMR).
Persistence, however, is a proxy for adherence, and filling large prescriptions (≥90-day supplies) has been associated with oversupplies. 3 Existing literature on oversupplies, which we refer to as overpersistence, is limited and has not been examined in the context of diabetes. Prior studies using persistence capture overpersistence as good persistence defined as filling ≥80% of medications. 4 Little is known, therefore, about the association of overpersistence with relevant clinical out-comes. The primary aim of this study was to characterize the association of different levels of persistence, including overpersistence, with attainment of goal hemoglobin A 1c (A1C), a measure of glycemic control. The secondary aim was to examine the association of persistence levels with A1C improvement.
Methods

SETTING
We conducted a retrospective cohort study examining persistence to diabetic pharmacotherapy after the initial receipt of any oral hypoglycemic prescription including metformin, sulfonylureas, thiazolinediones, and other agents in the VA. The VA provides comprehensive services to over 4.6 million veterans and 2 million additional health-care beneficiaries through 163 medical centers. 5 It boasts a fully integrated EMR system containing pharmacy data, health-care utilization information, ICD -9 codes, demographic and clinical information, as well as laboratory data. 6 In addition, most patients who used the VA for pharmaceutical services from January 1, 2000, through December 31, 2002, paid only $2.00-7.00 per prescription, decreasing the likelihood that patients would fill their prescriptions elsewhere. 7 Study data were obtained from the national VA Pharmacy Benefits Management (PBM) database. Accuracy of medication data is verified and updated on a monthly basis. The PBM database includes every patient with activity at any VA facility or pharmacy. The data also contain dosing instructions for each prescription and medications filled at the Consolidated Mail Outpatient Pharmacy. Laboratory results and outpatient clinical variables were obtained through the VA Decision Support System (DSS). The VA DSS is a longitudinal secondary relational database combining selected financial and clinical records in the VA.
STUDY SAMPLE
Our baseline date was the date the first diabetic medication was filled within the VA. The observation period for each patient was 12 months, beginning from the baseline date. To limit the analysis to adults with newly medicated type 2 diabetes, we included only patients who filled at least 1 prescription starting at the baseline date and no prescriptions for diabetes during the 12 months preceding their baseline date. This approach attempted to ensure that patients used the VA pharmacy system but had not previously filled an oral hypoglycemic prescription.
Patients meeting eligibility criteria were ≥18 years of age, filled at least 2 prescriptions for any oral hypoglycemic for the first time between January 1, 2000, and December 31, 2002, were alive 12 months after the index date, and had a follow-up A1C determined within 3 months of the end of the observation period (365 days), as seen in Figure 1 . We excluded patients whose index medication was insulin, as measuring persistence to injectable agents such as insulin is difficult using only pharmacy refill data. Those who started insulin during the observation period were retained in all analyses.
PRIMARY PREDICTOR VARIABLE: PERSISTENCE
Our primary predictor variable was persistence, defined as:
Total days supply of index oral hypoglycemic Days between (first date of first fill) -(first date of last fill) It requires at least 2 fills for calculation and therefore excludes individuals who fill a prescription only once (Appendix I). This method provides information on the continuity of refilling behavior, but does not provide a uniform denominator of time. It typically ranges from 0 to 1.00, in which higher values indicate higher medication persistence.
The Annals of Pharmacotherapy I 2010 May, Volume 44 I 801 theannals.com Due to variations in days supply, values >1.00 are possible. We defined nonpersistence as <0.80, good persistence as ≥0.80-1.10, and overpersistence as >1.10. 8 Adjustments were made for any time the patient was hospitalized. The quantity of medication dispensed to cover the number of hospitalized days was subtracted from the numerator and the denominator (number of days supplied by each refill).
PRIMARY OUTCOME VARIABLE: GLYCEMIC CONTROL
We assessed 2 metabolic outcomes: goal A1C and improved A1C. The 2 outcomes were dichotomous and defined, respectively, as last A1C ≤7.0% versus last A1C >7.0% and last A1C less than baseline A1C versus last A1C greater than baseline A1C. We included subjects with no change in A1C from baseline to the end of the observation period and defined them as "not improved."
OTHER ASSESSMENTS
Comorbidity was assessed based on ICD -9 codes collected from the Austin Automation Center (Austin, TX) recorded anytime from 12 months before to 6 months after the index date. For comorbidity to be considered present, we required 2 separate outpatient codes or 1 inpatient code. This method of defining comorbidities has been used in other work and has been shown to improve the validity between ICD -9 codes and other sources. 6, 9 We measured the prevalence of 8 comorbid conditions based on their known association with adherence or clinical association with diabetes or self-management skills. The prevalence of the following conditions was examined: hypertension, hyperlipidemia, coronary artery disease, stroke, psychiatric illnesses (other than depression), depression, alcohol dependence and/or abuse, and illicit substance dependence and/or abuse. Depression, alcohol use, and drug use were retained as single items because each has been described as a determinant of adherence. 10- 12 The baseline A1C value was defined as that value closest to the index date ± 3 months. The last A1C was defined as that value closest to the (index date + 365 days) ± 3 months. This reflects the clinical judgment that A1C represents glucose control over 3 months. Endocrinology and primary care encounters were determined using the corresponding DSS stop codes (306 and 323, respectively), which are identifiers that indicate the clinic within the VA where treatment was given. Patient age was calculated at the date of the index fill. The number of oral hypoglycemics represents a sum of discrete oral hypoglycemics filled over the observation period. The sulfonylureas include glipizide, glyburide, chlorpropamide, tolazamide, and tolbutamide; the thiazolidinediones include pioglitazone, rosiglitazone, and troglitazone; and the "other" category includes repaglinide, nateglinide, acarbose, and miglitol. The combination class of drugs represents taking more than 1 pill simultaneously, and the metformin and glyburide class is a single pill combining these 2 medications. Insulin started during the year was recorded as a binary variable.
ANALYSES
All analyses were conducted in accordance with an analysis plan developed before the study. Persistence was calculated for the entire study sample, as were age, sex, index drug class, comorbidity, and clinical characteristics, using SAS version 9.1.1 (Cary, NC). The association of diabetic metabolic control with patient demographic, clinical, and persistence characteristics was modeled using bivariate and multivariable statistical methods. Approval was obtained from the Human Investigation Committee at the Yale School of Medicine and the VA Connecticut Human Subjects Subcommittee.
Because the prevalence rates of our outcomes of glycemic control were not small, we estimated risk ratios directly using SAS PROC GENMOD rather than odds ratios. 13, 14 We analyzed both dichotomous and ordinal persistence groupings because of their non-normal distribution. We dichotomized persistence using the accepted threshold of <0.80 (nonpersistence) or ≥0.80 (good persistence). In a separate analysis, persistence was also considered an ordinal variable (<0.80, ≥0.80 -1.10, >1.10) with persistence ≥0.80-1.10 as the referent.
Indicator terms were created for age, race, number of oral hypoglycemics, class of diabetes medication, and comorbidity with the following respective referents: age <50 years, white race/ethnicity, 1 oral hypoglycemic (metformin), and zero comorbid conditions. The final model was adjusted for all variables seen in Tables 2 and 3 . These variables were statistically significant in bivariate analysis at the p < 0.05 level. The convergence criteria for all logistic models were satisfied.
Results
The median age of the subjects was 63 years, 67% were white, and 97% were male (Table 1) . Subjects filled a median of 1 oral hypoglycemic prescription during the entire observation period and had a median of 4 (interquartile range 3-6) visits to primary care providers. Twenty-seven percent saw an endocrinologist during the year. Median baseline A1C was 7.7% with a median change of -0.8%. Seventy-three percent of patients lowered their A1C by the end of the year, 24% showed a worse A1C, and 3% had no change in their A1C from baseline to study end. Sixty-five percent of patients achieved A1C ≤7.0%. Fewer than 4% of patients filled any prescription for insulin during the observation period. Seventy-seven percent of patients had good persistence (≥0.80). When we ordinalized persis-tence, only 52% of subjects achieved good persistence, with 25% categorized as overpersistent.
PERSISTENCE AND GLYCEMIC CONTROL
Good persistence was independently associated with goal A1C (RR 1.07; 95% CI 1.06 to 1.09) when compared to nonpersistence (Table 2) . Good persistence was also associated with improved A1C (RR 1.06; 95% CI 1.05 to 1.07) when compared to nonpersistence. Baseline A1C demonstrated a robust influence on A1C achieved, while insulin use showed a strong inverse association with achieving goal A1C (RR 0.67; 95% CI 0.63 to 0.71) and improved A1C (RR 0.88; 95% CI 0.85 to 0.90) at 1 year.
Older subjects were more likely to achieve goal A1C of ≤7.0% with a monotonic increase as age increased by decades, and those of nonwhite race were less likely to reach goal A1C. Both endocrinologist care (RR 1.04; 95% CI 1.03 to 1.05) and 1 or 2 comorbid conditions (RR 1.04; 95% CI 1.03 to 1.05) were associated with achieving goal A1C compared to no endocrinologist care and no comorbidity. Markers of diabetes severity, such as filling prescriptions for ≥2 different oral hypoglycemics in the year, were associated with lower likelihood of achieving goal
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OVERPERSISTENCE AND GLYCEMIC CONTROL
In this cohort, 25% of patients had persistence >1. 10 . In multivariable analysis, overpersistent patients were less likely to achieve goal A1C (RR 0.95; 95% CI 0.94 to 0.97) compared to patients with good persistence (≥0.80-1.10), but were more likely to achieve goal A1C than were those with nonpersistence (RR 0.93; 95% CI 0.92 to 0.94) after adjustment for demographics, comorbidity, care, and regi-men characteristics ( Table 3 ). The same was true when examining the outcome of improved A1C. Overpersisters were less likely to improve (RR 0.98; 95% CI 0.98 to 0.99) compared with good persisters, but were more likely to improve than were nonpersisters (RR 0.94; 95% CI 0.93 to 0.95) after adjustment for the characteristics listed in Table 3 .
Discussion
Persistence demonstrated a strong and consistent positive association with both measures of glycemic control in our sample of diabetic veterans new to oral hypoglycemic therapy. Controlling for patient and clinical factors did not diminish the association of persistence and glycemic control. Other studies using claims data have shown similar results. A retrospective study of 1668 diabetes management program patients demonstrated a strong association with A1C goal attainment and refill adherence to sulfonylureas or metformin determined with the same measure of persistence as ours over a 9-month period. 15 Schectman et al. also found an association between persistence and A1C improvement in 810 adults receiving diabetes care at a single university-based internal medicine clinic. 16 Pladevall et al. demonstrated an association between adherence to oral hypoglycemic agents measured using claims data and A1C improvement among 677 adults with diabetes, hyperlipidemia, and hypertension participating in a health maintenance organization. 17 In all studies, the subjects had prevalent diabetes at baseline. Our main finding confirms prior work, but uses a much larger national sample and an incident diabetic population, highlighting the value of early persistence surveillance.
By the end of the study year, 77% of veterans achieved the threshold of 80% refill, which is generally recognized as good persistence. The significant associations between persistence and A1C outcomes confirm assumptions that adherence is important for glycemic control, thus making the measure relevant for monitoring and intervention. Good persistence demonstrated the strongest association with both outcomes of metabolic control after baseline A1C, insulin use, ≥3 hypoglycemics filled in the year (all possible markers for diabetes severity), and age (Table 2) . Thus, persistence is an important modifiable determinant of glycemic control and deserves more clinical attention.
Younger subjects and those who were not white were less likely to achieve goal A1C, as has been shown in previous studies. 17, 18 Insulin use was also inversely associated with both glycemic outcomes. One explanation is that patients who fill insulin prescriptions may have higher A1C than those who do not take insulin, although both baseline A1C and insulin use were included in the multivariable model and
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The Annals of Pharmacotherapy I 2010 May, Volume 44 I 805 theannals.com each still demonstrated a strong negative association with glycemic control. It may also be that insulin is more difficult for patients to administer than simply taking a pill. Lastly, it may take more trial and error to titrate insulin to the correct dose to control glucose, so patients may have worse glycemic control until a stable insulin regimen is established. Conversely, having seen an endocrinologist was positively associated with both measures of glycemic control. This may be related to the finding that specialists are more likely to intensify therapy in diabetes. 19 Given the time and effort the VA places on process measures of diabetes in the primary care clinics, this finding was a bit surprising. Future work should explore the extent to which endocrinology and primary care diabetes visits differ and adapt the best practices from endocrinology to the primary care setting.
When persistence was ordinalized, overpersistence demonstrated intermediate associations with both goal A1C and improving A1C when compared to nonpersistence and good persistence. Our findings are consistent with Steiner et al.'s finding that overpersistent patients with epilepsy had lower phenytoin concentrations than persistent patients. 8 We chose 1.10 as the upper boundary of good persistence because it allows for a 10% grace period of overfilling medications to reflect the real-world practice of obtaining refills before the total drug on hand is used. Rather than represent pill hoarding, this likely represents a desirable practice to minimize any gaps in medication taking. Persistence >1.10, or oversupplies, however, may not represent careful pill-taking behavior, despite the fact that patients have medication on hand; this merits study in future work.
To our knowledge, this study is among the first to explore the issue of overpersistence in diabetes. One explanation for our finding that overpersistent patients may be less likely to achieve goal A1C or improve A1C is the fact that they are sicker than other patients, as evidenced by their higher baseline A1C and higher prevalence of comorbidities and hospitalizations. Another explanation could be that pharmacy records may not accurately reflect instructions for medication taking. It is not uncommon for a physician to increase the dose of an existing drug without issuing a new prescription to the patient, potentially resulting in misclassification of some patients in our data set. These same patients may have more aggressive disease and require more experimentation in the first year of therapy to achieve the proper diabetes regimen. This increased medication turbulence strengthens the argument that overpersistent patients may benefit from adherence monitoring and possibly intervention, rather than lumping them with patients who demonstrate good persistence.
Existing literature on overpersistence is limited and conflicting. One study in the VA found that populations receiving large supplies (≥90 days) at one time obtained a mean of 129% of all maintenance drugs given in large supplies compared to prescriptions <90 days. 3 In contrast, a study of antihypertensive medications by Christensen found that prescriptions of <60 days demonstrated "overcompliance" nearly 40% of the time compared with prescriptions of 61-120 days. 20 In our data, days supplied by each prescription was a median of 60 days for patients with good persistence. Taken together, these data suggest that overpersistence cannot simply be considered an artifact of prescription size. Finally, the clinical implications of overpersistence will vary across disease conditions. For diabetes, patients in this intermediate category were less likely to achieve goal A1C. For other diseases, such as HIV, persons in the intermediate category had a higher risk for developing resistance to antiretroviral drugs. 21 Researchers and clinicians alike should be cautious when dichotomizing persistence, as overpersistence may represent a category of subjects who differ from those with good persistence and nonpersistence.
Our findings should be interpreted with the following caveats. Persistence metrics rely on pharmacy records and do not directly measure ingestion of medications. Additionally, last A1C value and last fill could have been separated by up to 3 months. Further, our results may be subject to issues of treatment group selection, as in any observational study design. Medications and referrals to endocrinology specialists must be interpreted with this limitation in mind, although our data do reflect real-world practice. Our population included only veterans, who may differ from the national population. It follows that our data capture only VA-based care, including hospitalizations and outpatient visits. Also, given that our study was a secondary analysis of existing data, we relied on ICD -9 codes for the determination of comorbidities. Lastly, our study sample represents patients who are new to oral hypoglycemic therapy, not necessarily newly diagnosed with diabetes.
The study also has important strengths. We selected a cohort of veterans who had used the VA pharmacy at least 12 months prior to filling their first oral hypoglycemic medication in an effort to ensure that patients were new to these drugs rather than new to the VA pharmacy. We were also able to adjust for demographic variables; clinical variables such as number of visits to primary care, endocrinology, and hospitalizations; treatment-specific factors, such as number of diabetes medications used in the year and which index medication was started; comorbidities; and baseline A1C.
Good persistence was associated with glycemic control. Overpersistent patients were common and more likely than patients who were nonpersistent, but less likely than those with good persistence, to attain goal A1C. Estimating these different strata of persistence in clinical practice may be one strategy to improve awareness of adherence issues for both patients and providers and potentially identify patients at risk of poor glycemic control. Unlike other adherence measurements, such as self-report, pill count, or medication event monitoring systems, persistence is an objective measure that does not rely on provider or patient action. Because the pharmacy data needed to calculate persistence EXTRACTO TRASFONDO: Aunque la falta de adherencia a medicamentos contribuye a un control inadecuado de glucosa en pacientes con diabetes, la misma no se mide usualmente. La persistencia, repetición continua del despacho de medicamentos , es una medida que se puede integrar en la práctica clínica si se puede demostrar que se relaciona con el control glucémico.
OBJETIVO: Caracterizar la asociación de los niveles de persistencia (ninguno, bueno, sobre persistencia) con las concentraciones de hemoglobina A 1c (A1c) durante un año en pacientes de la Administración de Veteranos que reciben por primera vez medicamentos para manejar su diabetes.
MÉTODOS:
Los pacientes veteranos mayores o igual a 18 años de edad y que por primera vez recibían una prescripción de un agente hipoglucemiante oral (OHA) durante el período de 1 de diciembre de 2000 hasta el 31 de diciembre de 2002, fueron elegibles para el estudio. La fecha del primer despacho del OHA se definió como la fecha base. Los pacientes tenían que haber repetido por lo menos una prescripción para cualquier medicamento que no fuera para diabetes, durante los 12 meses previos a la fecha base. La persistencia se midió como la proporción entre el número de días de suplido de medicamentos y los 365 días del año. No persistencia se definió como una proporción menor de 0.8, un buen nivel de persistencia se definió como una proporción entre ≥0.8-1.10 y sobre persistencia se definió con una proporción mayor de 1.10. La variable principal del resultado era obtener la meta de A1c ≤7.0% luego de un año de iniciado el tratamiento.
RESULTADOS:
En el estudio se incluyeron 56,181 pacientes veteranos. La mayoría eran varones (97%), blancos (67%) y presentaban como comorbilidad hipertensión (58%) e hiperlipidemia (40%). La edad mediana fue de 63 años y la mediana de A1c de base fue de 7.7%. El cincuenta y dos por ciento (52%) de los pacientes tuvieron buen nivel de persistencia. Veinte y cinco por ciento (25%) de los pacientes presentaron sobre persistencia. El buen nivel de persistencia se asoció con obtener la meta de A1c (RR 1.07; 0.95% CI 1.06 y 1.09). La asociación de sobre persistencia fue menor que la del buen nivel de persistencia (RR 0.95; 95% CI 0.94 y 0.97) para obtener la meta de A1c, pero fue mayor que en los pacientes que presentaron no persistencia (RR 0.93; 95% CI 0.92 y 0.94).
CONCLUSIONES: El buen nivel de persistencia con el uso de los medicamentos hipoglucemiantes orales se asoció con buen control glucémico. Pacientes con sobre persistencia son comunes y están más asociados que los que tienen ninguna persistencia a obtener la meta de A1c; aunque en menor grado que los pacientes con buen nivel de persistencia. El estimar estas diferencias en niveles de persistencia puede ser útil para identificar pacientes que están a riesgo de presentar pobre control glucémico. RÉSULTATS: Un total de 56,181 vétérans furent inclus. Ceux-ci étaient des hommes (97%) et blancs (67%), avec des facteurs de comorbidités telles que l'hypertension (58%) et l'hyperlipidémie (40%). L'âge médian fut de 63 ans et la valeur de donnée de départ médiane de l'A1c fur de 7.7%. 52% des patients ont présenté une bonne persistance et 25% ont présenté une sur-persistance. Une bonne persistance fut liée à une valeur finale de l'A1c de 1.07 (avec un intervalle de confiance à 95% 1.06 à 1.09). L'association de la sur-persistance avec le même résultat (0.95 avec un intervalle de confiance à 95% 0.94 à 0.97) fur plus bas que la bonne persistance, mais plus élevé que la non persistance (0.93 avec un intervalle de confiance a 95% 0.92 à 0.94).
CONCLUSIONS:
La bonne persistance fut liée à un control glycémique. Les patients sur-persistants furent fréquents, plus probables, d'atteindre la valeur final de l'A1c a par rapport aux non-persistants. Cependant, ils furent moins probables d'atteindre cette valeur vis-à-vis des bons persistants. L'estimation de ces différentes strates à persistance pourrait être utile pour l'identification des patients à risque lors un control glycémique de mauvaise qualité. 
